90Y-DOTALAN (90Y-Lanreotide, 90Y-Somatulin) is a generic drug that specifically binds to somatostatin receptors and can be used for treating neuroendocrine neoplasms. The drug is currently not under development.
90Y-Lanreotide demonstrated efficacy in patients with NET but did not bring an advantage compared to other molecules that were under development at the same time. The molecule was tested in humans up to Phase I/II but was not convincing enough to replace molecules that were at a more advanced stage. The development of this molecule is on hold. The alternative on the market is presently 177Lu-Oxodotreotide.
Target/Mechanism: Somatostatine receptors
Leading Emitter: beta electrons (β–)